Posts by: Joana Carvalho

Joana Carvalho

Joana holds a BSc in Biology, a MSc in Evolutionary and Developmental Biology and a PhD in Biomedical Sciences from Universidade de Lisboa, Portugal. Her work has been focused on the impact of non-canonical Wnt signaling in the collective behavior of endothelial cells — cells that made up the lining of blood vessels — found in the umbilical cord of newborns.

April 20, 2020April 20, 2020

Potential Targeted Therapy for Cancer Shows Promise for Gaucher Disease, Study Finds

News

A targeted therapy currently being investigated for treating certain types of cancer can overcome some of the limitations of standard enzyme replacement therapy and be a promising therapeutic avenue for Gaucher ... Read more

April 13, 2020April 13, 2020

Imaging Technique May Help Monitor Gaucher Severity, Treatment Response, Study Says

News

Magnetic resonance spectroscopy (MRS) — a specialized imaging test to visualize and measure the amount of fat in certain regions of the body — may help monitor disease severity and ... Read more

February 24, 2020February 24, 2020

Blood Levels of CCL18 Can Assess Gaucher Severity in Clinical Practice, Study Suggests

News

The levels of a molecule known as CCL18 in the blood can be used in routine clinical practice to assess disease severity in patients with Gaucher disease, a study reports. ... Read more

January 16, 2020January 16, 2020

Avrobio Cleared to Expand to the U.S. its Gene Therapy Trial for Gaucher Disease

News

The U.S. Food and Drug Administration (FDA) has approved Avrobio‘s application to expand to the U.S. its ongoing Phase 1/2 trial testing its gene therapy candidate AVR-RD-02 in people with type ... Read more

August 8, 2019

Ways Needed to Ease High Cost of Gaucher Care to Patients and State in Iran, Study Says

News

Gaucher disease is among the more costly of chronic diseases to treat in Iran, and efforts are needed to minimize the financial burden facing patients and health authorities in the ... Read more

June 24, 2019June 24, 2019

Cerdelga Has Favorable Long-term Safety Profile in Patients with Type 1 Gaucher Disease, Pooled Trial Data Show

News

Cerdelga (eliglustat) has a favorable long-term safety profile consistent with previous observations among patients with type 1 Gaucher disease, pooled data from four completed trials show. The findings of the ... Read more

March 5, 2019

Aneurysms in Spleen Artery Underreported in Gaucher Patients, Case Report Says

News

Although rare, aneurysms of the splenic artery are most likely underreported among patients with Gaucher disease, a case report study says. The case report, “Splenic Artery Aneurysms, a Rare Complication ... Read more

August 9, 2018

Elelyso Clears Disease Cells from Bone Marrow of GD Type 1, Study Reports

News

The plant-based enzyme replacement therapy Elelyso (taliglucerase alfa) improves bone marrow response in adult patients with type 1 Gaucher disease, according to researchers. The findings of the study, “Improvement in bone marrow ... Read more